Core Viewpoint - The company has implemented a "Quality Improvement and Efficiency Enhancement Return Action Plan" for 2025, focusing on optimizing operations and enhancing returns to investors while navigating market challenges and opportunities [1]. Group 1: Business Performance and Strategy - The company has centered its operations around gene sequencing, leading to sustained growth across three major business lines despite competitive pressures and price declines in the industry [2][3]. - The company achieved a historical high in sales of its all-read long sequencing business (SEQ ALL), with over 700 units sold, marking a year-on-year growth of 60.35% [2]. - The company has expanded its global footprint, with cumulative sales of gene sequencing instruments exceeding 5,300 units, indicating a significant milestone [2]. Group 2: Market Expansion and Development - The company is actively pursuing a global strategy, focusing on diversifying its market presence in regions like Europe, Africa, and the Middle East to mitigate risks associated with single-market dependency [1][3]. - In the Asia-Pacific region, the company has successfully delivered 50,000 samples for the Thailand Genome Project and is advancing projects in Indonesia and South Australia [4]. - The company has established new customer relationships in various regions, including 22 new clients in the Asia-Pacific and 28 in the Americas, enhancing its market penetration [5][6]. Group 3: Product Development and Innovation - The company is advancing its product lines by integrating short-read and long-read sequencing technologies, aiming for automation and intelligent solutions in laboratory processes [9][10]. - The company has achieved significant growth in its multi-omics business, with revenue increasing by over 40% year-on-year, driven by product upgrades and market expansion [3][10]. - The company has obtained numerous certifications for its high-throughput sequencing products, enhancing its competitive edge in global markets [10]. Group 4: Financial Management and Efficiency - The company has invested approximately 1.574 billion RMB in its initial public offering projects, focusing on the development of semiconductor-based sequencing instruments and marketing service centers [8]. - The company is enhancing its financial management by improving accounts receivable turnover and optimizing credit management to accelerate cash flow [8][9]. - The company is implementing budget management strategies to align expenses with revenue forecasts, thereby improving operational efficiency [9]. Group 5: Governance and Compliance - The company has established a market value management system to enhance compliance and protect the rights of investors and stakeholders [11]. - The company has improved its ESG ratings, achieving an AA rating from Wind ESG, reflecting its commitment to sustainable development and enhancing investor confidence [11]. - The company is actively engaging with investors through various communication channels, including online and offline meetings, to foster transparency and trust [12].

证券代码：688114 证券简称：华大智造 公告编号：2025-055 深圳华大智造科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据中国证券监督管理委员会(以下简称"证监会")发布的《上市公司募集资金监管 规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等相关规定， 深圳华大智造科技股份有限公司(以下简称"公司"或"本公司")就 2025 年半年度募集 资金存放、管理与实际使用情况作如下专项报告： 一、募集资金基本情况 (一) 实际募集资金情况 公司首次公开发行股票注册的批复》(证监许可[2022]1638号)核准，公司首次公开发行每 股面值人民币1.00元的人民币普通股(A股)41,319,475股，每股发行价格人民币87.18元， 募集资金总额人民币3,602,231,830.50元，扣除与募集资金相关的发行费用总计人民币 会计师事务所(特殊普通合伙)对截至2022年9月6日公司此次公开发行股票的募集资金到账 情况进行了审验，并出具了《深圳华大智造科技股份有限公司IPO企业首次 ...

Core Viewpoint - The company has announced a stock incentive plan involving the grant of 6.555 million restricted stocks, accounting for 1.58% of the total share capital, aimed at enhancing corporate governance and retaining talent [1][3][5]. Summary by Sections Stock Incentive Plan Purpose and Principles - The purpose of the incentive plan is to improve corporate governance, establish a long-term incentive mechanism, attract and retain talent, and align the interests of shareholders, the company, and employees [1][3]. Stock Incentive Method and Source - The incentive method involves the issuance of second-class restricted stocks, sourced from repurchased shares or newly issued A-shares directed to incentive recipients [3][4]. Number of Rights Granted - The plan proposes to grant a total of 6.555 million restricted stocks, representing 1.58% of the company's total share capital of 41.56376 million shares [1][5]. Determination of Incentive Recipients - Incentive recipients include directors, senior management, core technical personnel, and key business staff, excluding independent directors and supervisors [4][5]. Distribution of Restricted Stocks - The distribution of restricted stocks among recipients is detailed, with 97.25% allocated to business backbone personnel [5]. Validity Period of the Incentive Plan - The plan is valid from the date of stock grant until all granted stocks are vested or become invalid, with a maximum duration of 36 months [6]. Granting and Vesting Conditions - The grant price for the restricted stocks is set at 26.15 yuan per share, with specific conditions for granting and vesting based on performance metrics [9][10]. Performance Assessment Metrics - The performance assessment will consider revenue growth excluding impacts from public health events, with specific targets set for the years 2024 and 2025 [12][13]. Accounting Treatment and Impact on Financial Performance - The plan's implementation will affect the company's accounting costs, with estimated expenses to be amortized over the vesting period [23][24]. Rights and Obligations of the Company and Recipients - The company retains the right to cancel unvested stocks if performance conditions are not met, while recipients must fulfill tax obligations related to the granted stocks [25][26].

Core Viewpoint - Shenzhen BGI Genomics Co., Ltd. plans to revise its 2024 restricted stock incentive plan and employee stock ownership plan to enhance employee motivation and align with the company's strategic goals in the context of the evolving market environment [10][11]. Summary by Sections Incentive Plan Overview - The incentive plan involves granting restricted stocks to key personnel, including directors, senior management, and core technical staff, to align their interests with the company's long-term performance [1][4]. Necessary Procedures - The company has followed necessary procedures, including board meetings and shareholder approvals, to implement the incentive plan and employee stock ownership plan [5][6][7]. Revision Reasons - The revision is driven by the need to adapt to changes in the external environment and to focus on increasing market share in the gene sequencing equipment sector, which is critical for long-term revenue growth [10][11]. Revised Performance Metrics - The revised performance metrics will include non-related party gene sequencing instrument sales as a key performance indicator, aiming to enhance the company's competitive position and employee engagement [11][12]. Conclusion - The independent financial advisor confirms that the revisions to the incentive plan and employee stock ownership plan have met the necessary review and disclosure obligations and are pending shareholder approval for implementation [14][15].

证券代码：688114 证券简称：华大智造 公告编号：2025-051 深圳华大智造科技股份有限公司 关于修订 2024 年限制性股票激励计划及 2024 年员工持股计划 相关文件的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳华大智造科技股份有限公司（以下简称"公司"或"华大智造"）于 议，审议通过《关于公司〈2024年限制性股票激励计划（草案修订稿）〉及摘要 的议案》《关于公司〈2024年限制性股票激励计划实施考核管理办法（修订稿）〉 的议案》《关于公司〈2024年员工持股计划（草案修订稿）〉及摘要的议案》《关 于公司〈2024年员工持股计划管理办法（修订稿）〉的议案》。为发挥激励作用， 达到激励目的，公司董事会认为应当新增2024年限制性股票激励计划（以下简称 "本激励计划"）、2024年员工持股计划所涉公司层面业绩考核指标，同意对《2024 年限制性股票激励计划（草案）》《2024年限制性股票激励计划（草案）摘要公 告》 《2024年限制性股票激励计划实施考核管理办法》 《2024年员工持股计划（草 司2024年限制性股票激励计划（草案）〉 ...

深圳华大智造科技股份有限公司 深圳华大智造科技股份有限公司（以下简称"公司"）为进一步完善公司法 人治理结构，健全公司的长效激励约束机制，吸引留住优秀人才，充分调动公司 员工的积极性，有效将股东利益、公司利益和员工利益三者紧密结合，共同促进 公司的长远发展，确保公司发展战略和经营目标的实现，公司拟实施 2024 年限 制性股票激励计划（以下简称"股权激励计划"或"限制性股票激励计划"）。 为保证股权激励计划的顺利实施，现根据《中华人民共和国公司法》《中华 人民共和国证券法》 《上市公司股权激励管理办法》 《上海证券交易所科创板股票 上市规则》《科创板上市公司自律监管指南第 4 号——股权激励信息披露》等有 关法律、法规和规范性文件以及《深圳华大智造科技股份有限公司章程》、公司 《2024 年限制性股票激励计划（草案修订稿）》的相关规定，并结合公司的实际 情况，特制定 2024 年限制性股票激励计划实施考核管理办法（修订稿） （以下简 称"本办法"）。 一、考核目的 进一步完善公司法人治理结构，建立和完善公司激励约束机制，保证公司 进而确保公司发展战略和经营目标的实现。 二、考核原则 考核评价必须坚持公正、公开 ...

深圳华大智造科技股份有限公司 第一章 总则 第二条 持股计划的基本原则 第一条 为规范深圳华大智造科技股份有限公司（以下简称"华大智造"或"公司"） 施，根据《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共和国 证券法》以下简称"《证券法》"、中国证监会《关于上市公司实施员工持股计划试 点的指导意见》（以下简称"《指导意见》"）、《上海证券交易所科创板上市公司 自律监管指引第 1 号——规范运作》（以下简称"《自律监管指引第 1 号》"）等 相关法律、行政法规、规章、规范性文件和《公司章程》《深圳华大智造科技股份 有限公司 2024 年员工持股计划（草案修订稿）》之规定，特制定《深圳华大智造 科技股份有限公司 2024 年员工持股计划管理办法（修订稿）》（以下简称"本办法" 或"《持股计划管理办法》"）。 第二章 持股计划的制定 （一）依法合规原则 公司实施持股计划，严格按照法律、行政法规的规定履行程序，真实、准确、 完整、及时地实施信息披露。任何人不得利用持股计划进行内幕交易、操纵证券市 场等证券欺诈行为。 （二）自愿参与原则 公司实施持股计划遵循公司自主决定，员工自愿参加，公司不以摊派、强行 ...

Core Insights - BGI Genomics (688114) reported strong growth in its three main business segments: long-read sequencing (SEQALL), intelligent automation (GLI), and multi-omics (OMICS) despite challenging external conditions [1][2] - The company achieved a record sales volume of over 700 long-read sequencers in the first half of 2025, marking a significant year-on-year increase of 60.35% [1] - The G99 sequencer demonstrated strong competitive advantages in clinical applications, with reagent revenue increasing by 21.97% [1] Segment Summaries Long-Read Sequencing (SEQALL) - Sales volume exceeded 700 units, achieving a historical high for the same period [1] - The market share for nanopore sequencers in the domestic bidding market doubled compared to the previous year [1] - The E25 model showed exceptional performance with equipment revenue increasing by 361.44% and reagent revenue by 585.91% [1] Intelligent Automation (GLI) - Revenue for GLI reached 112 million yuan, with over 130 new sales [2] - The integration of artificial intelligence technology in life science tools has been deepened, with the launch of the self-developed PrimeGen [2] Multi-Omics (OMICS) - Adjusted revenue for OMICS experienced a significant growth of over 40% year-on-year [2] - The cell-omics platform is expanding into overseas markets through product upgrades and a collaborative marketing strategy [2] Strategic Outlook - BGI Genomics is positioned to expand its leading advantage amid the domestic replacement trend, supported by favorable policies and a robust technological barrier [2]

8月22日盘后，华大智造(688114.SH)发布2025年度中期业绩报告。报告显示，2025年上半年，公司实现 主营业务收入10.91亿元，归属于母公司所有者的净利润同比减亏65.28%。全读长测序业务作为公司核 心业务板块，上半年仪器新增销售量超700台，同比增长60.35%，创历史同期新高。 业务规模增长之外，华大智造提质增效成果同样显著。公司通过技术创新与精益管理双轮驱动，实现业 务规模与运营质量同步跃升。2025年上半年，公司归属于母公司所有者的扣非后净利润亏损同比收窄 37.55%。期间费用(不含财务费用)为8.27亿元，较去年同期下降17.04%。 产能及供应链方面，依托"基因测序仪产业链链主"企业的引领地位，公司联合50余家供应商攻坚核心原 材料，带动产业链整体效率提升25%，实现高本土化率与产业协同的双重突破。公司全球备件交付及时 率稳步提升至90%，其中中国区达91.04%，以72小时交付周期持续领跑行业。技术突破、管理优化、供 应链协同的三维发力，为公司长期价值创造与经营韧性构筑坚实底座。 当下，人工智能技术正成为驱动行业变革的关键动力。今年上半年，华大智造持续推进实验室智能自动 化(G ...

智通财经APP获悉，8月22日盘后，华大智造(688114.SH)发布2025年度中期业绩报告。报告显示，2025 年上半年，公司实现主营业务收入10.91亿元，归属于母公司所有者的净利润同比减亏65.28%。全读长 测序业务作为公司核心业务板块，上半年仪器新增销售量超700台，同比增长60.35%，创历史同期新 高。 业务规模增长之外，华大智造提质增效成果同样显著。公司通过技术创新与精益管理双轮驱动，实现业 务规模与运营质量同步跃升。2025年上半年，公司归属于母公司所有者的扣非后净利润亏损同比收窄 37.55%。期间费用(不含财务费用)为8.27亿元，较去年同期下降17.04%。 产能及供应链方面，依托"基因测序仪产业链链主"企业的引领地位，公司联合50余家供应商攻坚核心原 材料，带动产业链整体效率提升25%，实现高本土化率与产业协同的双重突破。公司全球备件交付及时 率稳步提升至90%，其中中国区达91.04%，以72小时交付周期持续领跑行业。技术突破、管理优化、供 应链协同的三维发力，为公司长期价值创造与经营韧性构筑坚实底座。 当下，人工智能技术正成为驱动行业变革的关键动力。今年上半年，华大智造持续推进 ...